Rosalind Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Rosalind Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-25,000	Closed	-$5.78M	–	36
2023 Q4	$5.78M	Buy	+25,000	New	+$4.37M	4.76%	9

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Rosalind Advisors's MDGL Position: Q1 2024 in Review

Rosalind Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2024, closing a stake of 25,000 shares — an estimated $5.78M sold.

Rosalind Advisors first reported a position in MDGL in Q4 2023 and held it in 1 quarter. The position peaked at $5.78M in Q4 2023. 268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.

Rosalind Advisors reported no remaining Madrigal Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Rosalind Advisors sold 25,000 Madrigal Pharmaceuticals shares in Q1 2024, an estimated $5.78M.
Rosalind Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Rosalind Advisors's Madrigal Pharmaceuticals position peaked at $5.78M in Q4 2023.
268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.

Based on Rosalind Advisors's 13F filing for Q1 2024, filed 25 Apr 2024.